Exam IV: Hemodynamic Disorders and Thromboembolic Diseases II Flashcards
Coagulation Cascade
Third arm of the hemostatic process
Amplifying series of enzymatic conversions
Each step proteolytically cleaves an inactive proenzyme into an activated enzyme
Culminates in thrombin formation
Thrombin is the most important coagulation factor because it can act at numerous stages in the process
Proteolytic Cascade
Thrombin converts the soluble plasma protein fibrinogen into fibrin monomers that polymerize into an insoluble gel converting the primary hemostatic plug into a secondary plug
Fibrin gel encases platelets and other circulating cells in the definitive secondary hemostatic plug
Fibrin polymers are covalently cross-linked and stabilized by factor XIIIa (which itself is activated by thrombin)
Clinical Assessments of Coagulation Dysfunction
Assess the function of the two arms of the coagulation pathway
Two standard assays:
1. Prothrombin time (PT)
2. Partial thromboplastin time (PTT)
PT Assay
Assesses the function of the proteins in the extrinsic pathway
Factors II, V, VII, X, and fibrinogen (2, 5, 7, 10)
Accomplished by adding tissue factor and phospholipids to citrated plasma (sodium citrate chelates calcium and prevents spontaneous clotting)
Coagulation is initiated by the addition of exogenous calcium and the time for a fibrin clot to form is recorded
PTT Assay
Partial thromboplastin time (PTT)
Screens for the function of the proteins in the intrinsic pathway
Factors II, V, VIII, IX, X, XI, XII, and fibrinogen (2, 5, 8, 9, 10, 11, 12)
Clotting is initiated through the addition of negative charged particles (ground glass)
Activates factor XII (Hageman factor), phospholipids, and calcium, and the time to fibrin clot formation is recorded
Thrombin
Exerts a wide variety of pro-inflammatory effects
Most effects of thrombin occur through its activation of a family of protease activated receptors (PARs)
PARs are expressed on endothelium, monocytes, dendritic cells, T lymphocytes, and other cell types
Thrombin Effects: neutrophil adhesion, monocyte activation, platelet aggregation with fibrin and TxA2, lymphocyte activation, endothelial activation
Anticoagulation Restriction
Coagulation cascade must be restricted to the site of vascular injury to prevent runaway clotting of the entire vascular tree
Three Categories of Endogenous Anticoagulants
- Antithrombins (antithrombin III): inhibit the activity of thrombin and other serine proteases, including factors IXa, Xa, XIa, and XIIa (9, 10, 11, and 12)
Antithrombin III is activated by binding to heparin-like molecules on endothelial cells
Clinical usefulness of administering heparin to minimize thrombosis since heparin is an anti-coagulant - Proteins C and S: vitamin K-dependent proteins that act in a complex that proteolytically inactivates factors Va and VIIIa
- Tissue Factor Protein Inhibitor (TFPI) is a protein produced by endothelium that inactivates tissue factor-factor VIIa complexes
Endothelial Cells
Fine-tune the coagulation/anticoagulation balance
Releasing plasminogen activator inhibitor (PAI)
Blocks fibrinolysis by inhibiting t-PA binding to fibrin
Confers an overall procoagulant effect
Production is increased by thrombin as well as certain cytokines
Fibrinolytic System: Fibrin Degradation Products
Endothelial cells release plasminogen activator inhibitors (PAI) to cause clot degradation; if you block PAI via tPA it won’t break down
What happens: “syrup” hardens and pieces flake off to get fibrin degradation products, which can be measured in the lab
Fibrin degradation products = indicate a clot was formed
Disseminated intravascular coagulation: disease where you see lots of clots and when they break down you see a lot of breakdown products
Virchow’s Triad
Three primary abnormalities that lead to thrombus formation (called Virchow’s triad):
- Endothelial injury
- Stasis or turbulent blood flow
- Hypercoagulability of the blood
When you have stasis, the blood is slowing down
Turbulent blood flow, fast moving, but there are spots that are slowed down = spots of clot formation
Endothelial Injury
Particularly important for thrombus formation in the heart or the arterial circulation
Normally high flow rates might otherwise impede clotting by preventing platelet adhesion and washing out activated coagulation factors
Thrombus is not a normal occurrence unless injury present (anywhere in vasculature)
Thrombus formation within cardiac chambers (i.e. after endocardial injury due to myocardial infarction)
Over ulcerated plaques in atherosclerotic arteries
Sites of traumatic or inflammatory vascular injury (vasculitis)
Endothelial Dysfunction
Endothelium does not need to be denuded or physically disrupted to contribute to the development of thrombosis
Any perturbation in the dynamic balance of the prothombotic and antithrombotic activities of endothelium can influence local clotting events
Induced by a wide variety of insults: Hypertension Turbulent blood flow Bacterial endotoxins Radiation injury Metabolic abnormalities: homocystinemia or hypercholesterolemia Toxins absorbed from cigarette smoke
Turbulence
Alteration of normal blood flow
Contributes to arterial and cardiac thrombosis by causing endothelial injury or dysfunction
Forming countercurrents and local pockets of stasis
Stasis is a major contributor in the development of venous thrombi
Arteries: most common cause of thrombosis is endothelial injury whereas in veins it is stasis
Normal Blood Flow
Normal flow is laminar
Platelets (and other blood cellular elements) flow centrally in the vessel lumen
Separated from endothelium by a slower moving layer of plasma
Stasis and Turbulence
Stasis and Turbulence:
Promote endothelial activation enhancing pro-coagulant activity
Disrupt laminar flow
Bring platelets into contact with the endothelium
Prevent washout and dilution of activated clotting factors via fresh flowing blood and inflow of clotting factor inhibitors
Hypercoagulability
also called thrombophilia- something is missing in the coagulation pathway
Less frequent contributor to thrombotic states
Any alteration of the coagulation pathways that predisposes to thrombosis
Divided into primary (genetic) and secondary (acquired) disorders which are a result of the primary disease
Inherited Hypercoagulation Diseases
Inherited causes (most common): Point mutations in the factor V gene Prothrombin gene
Homocysteine and Thrombosis
Elevated levels of homocysteine contribute to arterial and venous thrombosis
Prothrombotic effects of homocysteine due to thioester linkages
Rare Inherited Causes of Primary Hypercoagulability
Deficiencies of anticoagulants: antithrombin III, protein C, or protein S
Clinical presentation:
Begins in adolescence or early adulthood
Venous thrombosis
Recurrent thromboembolism
HIT Syndrome
Acquired thrombophilic states
Heparin-induced thrombocytopenia (HIT) syndrome
Occurs following the administration of unfractionated heparin
May induce the appearance of antibodies
Recognize complexes of heparin and platelet factor 4 on the surface of endothelial cells causing binding of antibodies to platelets and results in their activation, aggregation, and consumption
Prothrombotic state, even in the face of heparin administration and low platelet counts
Anti-Phospholipid Antibody Syndrome
AKA lupus anticoagulant syndrome
Autoantibodies induce a hypercoagulable state causing endothelial injury
Directly activates platelets and complement
Clinical manifestations:
- Recurrent thrombosis, repeated miscarriages, cardiac valve vegetations, and thrombocytopenia
- Pulmonary embolism, pulmonary hypertension, stroke, bowel infarction, or renovascular hypertension
- Fetal loss
Typical of younger patient that has lots of clots
Young adult who has had several miscarriages
Secondary Antiphospholipid Syndrome
Individuals with a well-defined autoimmune disease
Systemic lupus erythematosus